Oncoverity, Inc.
Clinical trials sponsored by Oncoverity, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental antibody may boost leukemia treatment Results expected Jan 2027 (estimated)
- New combo therapy for AML enters early human testing Results expected May 2027 (estimated)
-
Experimental antibody may boost leukemia treatment
Disease control OngoingThis phase 2 trial tests whether adding an experimental antibody called cusatuzumab to the standard drugs venetoclax and azacitidine helps people with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 140 adults who cannot have intensive chemotherapy. P…
Phase 2 • Sponsor: OncoVerity, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy for AML enters early human testing
Disease control OngoingThis early-phase study tests a new drug called cusatuzumab alongside usual treatments for adults with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The main goal is to check the safety and side effects of the combination. About 61 participants will receive …
Phase 1 • Sponsor: OncoVerity, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC